Skip to main content
Alan Landay

Alan Landay

Industry Collaboration Group member since 2012
Professor and Vice Chair Internal Medicine, Rush University

Alan Landay, PhD, is Professor in the Departments of Internal Medicine and Microbial Pathogens and Immunity and Vice Chair for Research in the Department of Internal Medicine at Rush University Medical Center in Chicago, USA. He is also Chief of the Division of Translational and Precision Medicine. He has been involved in HIV research for over 40 years, having performed some of the first immune evaluations of people living with haemophilia and HIV in 1981 while completing a postdoctoral fellowship at the University of Alabama, Birmingham. He collaborated with Abbott Labs in 1983 in helping develop the first HIV antibody test that was licenced by the FDA in 1985 for use in screening blood supply. His laboratory has made important original contributions in understanding the role of immune activation and inflammation in outcomes of non-communicable disease related to ageing in the HIV population.

Alan has been an investigator with the AIDS Clinical Trials Group (ACTG) for over 30 years and led the Rush Immunology Support Lab since its inception for 20 years. He has provided leadership to the ACTG Network labs as the Scientific Director of Laboratories and Chair of the Network Laboratory Steering Committee. In this role, he works with the domestic and international laboratories in integrating their work with the agendas of the Transformative Science Groups. He also provides laboratory leadership for ACTG protocol development and implementation as an ad hoc member of the Scientific Agenda Steering Committee. Here, he provides input on the scientific rationale for laboratory assays and the fiscal review of the assay cost. Alan provides leadership to the ACTG through committee and working group membership.

He was the founder of the Therapeutic Vaccine Focus Group under the Cure Transformative Science Group (TSG)and serves as the consulting immunologist to the TSG.  He has extensive experience in ageing-related studies and is co-investigator of an R33 grant that integrates efforts of the Center for AIDS Research, Older American Independence Centers and Shock Centers. He has participated on the Office of AIDS Research HIV and Aging Committee and has been an advisor to UNAIDS on HIV and ageing. Over the past 10 years, his research focus has been on studies of the human microbiome and metabolome and better understanding its role both in health and disease, resulting in over 40 peer-reviewed publications.

From 2020-2022, Alan served as a non-industry Co-Chair of the IAS Towards an HIV Cure: Industry Collaboration Group. He works extensively with industry in advancing the HIV cure agenda. More recently, he has focused his efforts on studies of COVID-19. He led the research effort on COVID-19 in the Department of Medicine at Rush and was the leader in establishing the COVID-19 biorepository. He also leads the COVID-19 lab efforts for the NIH-funded ACTG Lab group. Alan helped establish the PASC Clinic at Rush and the associated biorepository.

He has published over 500 peer-reviewed papers focused on basic and clinical studies of HIV with an emphasis on the role of immune activation, inflammation and microbiome in HIV pathogenesis, therapy ageing and cure research.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.